Advanced Malignant Tumor Clinical Trial
Official title:
A Phase I Clinical Trial Evaluating the Tolerance and Pharmacokinetics of TQB3909 Tablets in Patients With Relapsed or Refractory Advanced Malignant Tumors
TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3 / 7 activity and caspase 3 / 9 cleavage, and induces apoptosis.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05015309 -
A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor
|
Phase 1 | |
Not yet recruiting |
NCT06022250 -
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
|
Phase 1 | |
Recruiting |
NCT06059508 -
Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors
|
Phase 1 | |
Recruiting |
NCT05851092 -
Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
|
Phase 1 | |
Suspended |
NCT05089461 -
A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor
|
Phase 2 | |
Active, not recruiting |
NCT04296994 -
A Study of QL1706 in Subjects With Advanced Malignant Tumor
|
Phase 1 | |
Recruiting |
NCT05416359 -
Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04954456 -
A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies
|
Phase 1 | |
Recruiting |
NCT04326829 -
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT04739111 -
An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor
|
Phase 1 | |
Recruiting |
NCT05767060 -
BAT7104 Injection in Patients With Advanced Malignant Tumors.
|
Phase 1 | |
Recruiting |
NCT05144061 -
A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
Completed |
NCT05042908 -
Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04412564 -
A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
|
Phase 2 | |
Recruiting |
NCT05198505 -
Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05318833 -
A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors
|
Phase 1 |